Filing Flows

Filing Flows › Companies › Dare Bioscience › Cash flow

Dare Bioscience cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$6.9M in Q2 2026 · −$11.8M over twelve months

Operating cash flow−$6.8M
Capital spending−$81K
Free cash flow−$6.9M

Analysis

In Q2 2026, Dare Bioscience generated −$6.8M of operating cash flow and spent $81K on capital projects, leaving free cash flow of −$6.9M. That is $1.6M less than in Q2 2025 (−$5.3M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$11.3M; the largest uses were operating cash flow ($11.3M), other financing ($970K), capital spending ($462K); besides operations, cash came from shares issued ($20.3M); the cash balance rose by $7.6M.

Operating cash flow was −$6.8M against net income of −$3.0M. The largest differences: depreciation & amortization +$572K, prepaid and other assets −$322K, stock-based pay +$287K.

Free cash flow

Dare Bioscience: free cash flow by quarterDare Bioscience: free cash flow by quarter−$5.6MQ3 2024$4.7MQ4 2024−$5.6MQ1 2025−$5.3MQ2 2025−$617KQ3 2025$1.2MQ4 2025−$5.5MQ1 2026−$6.9MQ2 2026
Operating cash flow less capital spending.
Dare Bioscience: operating cash flow against capital spendingDare Bioscience: operating cash flow against capital spendingOperating cash flowCapital spending−$5.9M−$282KQ3 2024$5.3M$563KQ4 2024−$5.5M$157KQ1 2025−$5.4M−$153KQ2 2025−$442K$175KQ3 2025$1.4M$207KQ4 2025−$5.5M$0Q1 2026−$6.8M$81KQ2 2026
Latest (Q2 2026): Operating cash flow −$6.8M, Capital spending $81K.

Capital allocation, year by year

Dare Bioscience: where the cash came from (up) and went (down), by fiscal yearDare Bioscience: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$28.8MFY2021: Shares issued $16.3MFY2021: Capital spending −$15K$16.3MFY2021FY2022: Operating cash flow −$18.1MFY2022: Shares issued $1.4MFY2022: Capital spending −$63K$1.4MFY2022FY2023: Operating cash flow −$38.9MFY2023: Net borrowing $267KFY2023: Capital spending −$629K$267KFY2023FY2024: Operating cash flow $5.5MFY2024: Net borrowing −$579KFY2024: Shares issued $454KFY2024: Capital spending −$573K$5.9MFY2024FY2025: Operating cash flow −$9.9MFY2025: Net borrowing −$1.6MFY2025: Shares issued $20.9MFY2025: Capital spending −$385K$20.9MFY2025
Over these 5 years operating cash flow totalled −$90.1M; the largest uses were operating cash flow ($95.6M) and net borrowing ($2.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$12.6M
Debtnone
Net cash$12.6M
Due within a year$11K
Cash runway13 months

Dare Bioscience is burning cash: its operations consume cash, a free cash flow of −$11.8M a year at the current rate against $12.6M of cash and investments: a runway of about 13 months; $11K of debt also comes due within a year, which the cash covers before any new financing.

Where the cash came from and went

Dare Bioscience: sources (+) and uses (−) of cash, Q2 2026Dare Bioscience: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$6.8MCash drawn (+) / kept (−)$5.9MOther financing$785KShares issued$167KCapital spending−$81KExchange rates$2K
Dare Bioscience: sources (+) and uses (−) of cash, TTM to Q2 2026Dare Bioscience: sources (+) and uses (−) of cash, TTM to Q2 2026Shares issued$20.3MOperating cash flow−$11.3MCash drawn (+) / kept (−)−$7.6MOther financing−$970KCapital spending−$462KExchange rates$28K

From profit to cash

Dare Bioscience: net income to operating cash flow, Q2 2026Dare Bioscience: net income to operating cash flow, Q2 2026Net income−$3.0MDepreciation & amortization$572KStock-based pay$287KReceivables$124KAccrued liabilities−$80KPrepaid and other assets−$322KOperating cash flow−$6.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$6.8M−$81K—$167K$5.9M−$6.9M
Q1 2026−$5.5M—−$1.1M$95K$6.2M−$5.5M
Q4 2025$1.4M−$207K−$529K—−$1.6M$1.2M
Q3 2025−$442K−$175K−$122K—−$18.0M−$617K
Q2 2025−$5.4M$153K−$511K$475K$5.3M−$5.3M
Q1 2025−$5.5M−$157K−$187K$436K$5.4M−$5.6M
Q4 2024$5.3M−$563K−$187K—−$4.5M$4.7M
Q3 2024−$5.9M$282K−$125K—$5.2M−$5.6M

Dare Bioscience: income statement and cash flow

Dare Bioscience, Q2 2026: revenue $188K. The chart follows the revenue to costs, profit and cash.

Dare Bioscience: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.